Total medical devices industry M&A deals in September 2020 worth $9.86bn were announced globally, according to GlobalData’s deals database.
- Embed this chart
Embed this chart into your website
Copy and paste the code below into your website to display the chart.
The value marked a decrease of 42.6% over the previous month and a rise of 22.4% when compared with the last 12-month average, which stood at $8.06bn.
Comparing deals value in different regions of the globe, North America held the top position, with total announced deals in the period worth $9.35bn. At the country level, the US topped the list in terms of deal value at $9.35bn.
In terms of volumes, North America emerged as the top region for medical devices industry M&A deals globally, followed by Europe and then Asia-Pacific.
The top country in terms of M&A deals activity in September 2020 was the US with 18 deals, followed by Italy with two and Japan with one.
In 2020, as of the end of September 2020, medical devices M&A deals worth $96.13bn were announced globally, marking an increase of 207.2% year on year.
Medical devices industry M&A deals in September 2020: Top deals
The top five medical devices industry M&A deals accounted for 97.7% of the overall value during September 2020.
The combined value of the top five medical devices M&A deals stood at $9.64bn, against the overall value of $9.86bn recorded for the month.
The top five medical devices industry deals of September 2020 tracked by GlobalData were:
1) Illumina’s $8bn acquisition of Grail
2) The $780m acquisition of Advanced Instruments by Patricia Industries
3) Corza Health’s $415.4m asset transaction with Takeda Pharmaceutical
4) The $240m asset transaction with Integra LifeSciences by Smith & Nephew
5) CryoLife’s acquisition of Ascyrus Medical for $200m.
Verdict deals analysis methodology
This analysis considers only announced and completed deals from the GlobalData financial deals database and excludes all terminated and rumoured deals. Country and industry are defined according to the headquarters and dominant industry of the target firm. The term ‘acquisition’ refers to both completed deals and those in the bidding stage.
GlobalData tracks real-time data concerning all merger and acquisition, private equity/venture capital and asset transaction activity around the world from thousands of company websites and other reliable sources.
More in-depth reports and analysis on all reported deals are available for subscribers to GlobalData’s deals database.